Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 4Phase 1 3Phase 3 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 2Neuroblastoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Antibodies × Clear all
NCT02914405 2026-04-28

MiniVan

University Hospital Southampton NHS Foundation Trust

Phase 1 Active not recruiting
44 enrolled
CNS

Neuroblastoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
73 enrolled
Dermatologic

Melanoma

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
127 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡